Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganetespib in Metastatic CRPC Pretreated With Docetaxel
NCT01270880Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jan 2011
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ganetespib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Barbara Ann Karmanos Cancer Institute. Started Jan 2011; status: completed.
02
Drugs
ganetespib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01270880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01270880.